- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer immunotherapy: Breakthrough or “deja vu, all over again”?
Authors
Keywords
-
Journal
TUMOR BIOLOGY
Volume 39, Issue 6, Pages 101042831770776
Publisher
SAGE Publications
Online
2017-06-22
DOI
10.1177/1010428317707764
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- How I treat mycosis fungoides and Sezary syndrome
- (2016) S. Whittaker et al. BLOOD
- Survival of patients with advanced metastatic melanoma: The impact of novel therapies
- (2016) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma
- (2016) Sagar Lonial et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Histopathology of vaccine-preventable diseases
- (2016) Isaac H Solomon et al. HISTOPATHOLOGY
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- Cocktails for cancer with a measure of immunotherapy
- (2016) Heidi Ledford NATURE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
- (2016) David T. Rodgers et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Actions of l -thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells
- (2016) Hung-Yun Lin et al. STEROIDS
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
- (2015) P. A. Thompson et al. BLOOD
- Therapeutic cancer vaccines
- (2015) Cornelis J.M. Melief et al. JOURNAL OF CLINICAL INVESTIGATION
- New insights on the development of fungal vaccines: from immunity to recent challenges
- (2015) Natasha P Medici et al. MEMORIAS DO INSTITUTO OSWALDO CRUZ
- Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic
- (2015) Connie P.M. Duong et al. MOLECULAR IMMUNOLOGY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
- (2015) Alexander M. Lesokhin et al. Science Translational Medicine
- Interleukin 12: still a promising candidate for tumor immunotherapy?
- (2014) Witold Lasek et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
- (2014) David McDermott et al. CANCER TREATMENT REVIEWS
- New insights into IL-12-mediated tumor suppression
- (2014) S Tugues et al. CELL DEATH AND DIFFERENTIATION
- Vaccination against helminth parasite infections
- (2014) James P Hewitson et al. Expert Review of Vaccines
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
- (2014) H. S. Kuehn et al. SCIENCE
- Rituximab in the treatment of non-Hodgkin's lymphoma – a critical evaluation of randomized controlled trials
- (2013) Morag Meriel Griffin et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Therapeutic Cancer Vaccines: Current Status and Moving Forward
- (2012) J. Schlom JNCI-Journal of the National Cancer Institute
- Evolving Insights in the Pathogenesis and Therapy of Cutaneous T-cell lymphoma (Mycosis Fungoides and Sezary Syndrome)
- (2011) Henry K. Wong et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response
- (2010) Galit Eisenberg et al. CELLULAR IMMUNOLOGY
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
- (2010) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies
- (2009) M. Campoli et al. CLINICAL CANCER RESEARCH
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
- (2009) C B Reeder et al. LEUKEMIA
- Spontaneous regression of metastases from melanoma: review of the literature
- (2009) Louise Vennegaard Kalialis et al. MELANOMA RESEARCH
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started